Hereditary breast and ovarian cancer and reproduction: An observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors

Breast Cancer Research and Treatment

Volumn 145, Issue 3, 2014, Pages 673-681

  Derks Smeets, Inge A P ^a,b   De Die Smulders, Christine E M ^a,b   Mackens, Shari ^c   Van Golde, Ron ^a   Paulussen, Aimee D ^a,b   Dreesen, Jos ^a,b   Tournaye, Herman ^c   Verdyck, Pieter ^d   Tjan Heijnen, Vivianne C G ^a,b   Meijer Hoogeveen, Madelon ^e   De Greve, Jacques ^d   Geraedts, Joep ^a,b   De Rycke, Martine ^d   Bonduelle, Maryse ^d   Verpoest, Willem M ^c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

^d UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

BRCA1; BRCA2; Hereditary breast and ovarian cancer; Preimplantation genetic diagnosis; Reproductive outcome

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN;

ADULT; ARTICLE; ASYMPTOMATIC DISEASE; CANCER RADIOTHERAPY; CANCER SURVIVOR; CONTROLLED STUDY; CRYOPRESERVATION; DELIVERY; EMBRYO; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; GENE MUTATION; HAPLOTYPE; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HETEROZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MASTECTOMY; MUTATIONAL ANALYSIS; OBSERVATIONAL STUDY; ONCOGENE; PARTIAL MASTECTOMY; POLYMERASE CHAIN REACTION; PREGNANCY RATE; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REPRODUCTION; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; BREAST NEOPLASMS; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; OVARIAN NEOPLASMS; PREGNANCY; PREGNANCY OUTCOME;

ADULT; ASYMPTOMATIC DISEASES; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MALE; OVARIAN NEOPLASMS; PREGNANCY; PREGNANCY OUTCOME; PREIMPLANTATION DIAGNOSIS; PRENATAL DIAGNOSIS;

EID: 84901605844     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2951-5     Document Type: Article

References (39)

1. Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25(11):1329-1333
2. Cancer Research UK: Breast cancer incidence statistics. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/incidence/ uk-breast-cancer-incidence-statistics. Accessed 27 Feb 2014
3. Cancer Research UK: Ovarian cancer incidence statistics. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ovary/incidence/. Accessed 27 Feb 2014
4. Ford D, Easton DF, Peto J (1995) Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57(6):1457-1462
5. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I et al (2006) Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98(23):1694-1706
6. Goossens V, Traeger-Synodinos J, Coonen E, De Rycke M, Moutou C, Pehlivan T et al (2012) ESHRE PGD Consortium data collection XI: cycles from January to December 2008 with pregnancy follow-up to October 2009. Hum Reprod 27(7):1887-1911
7. Shenfield F, Pennings G, Devroey P, Sureau C, Tarlatzis B, Cohen J (2003) Taskforce 5: preimplantation genetic diagnosis. Hum Reprod 18(3):649-651
8. Tilstone C (2005) UK clinicians to screen embryos for BRCA mutations. Lancet Oncol 6(6):358
9. Menon U, Harper J, Sharma A, Fraser L, Burnell M, ElMasry K et al (2007) Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer. Hum Reprod 22(6):1573-1577
10. Staton AD, Kurian AW, Cobb K, Mills MA, Ford JM (2008) Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. Fam Cancer 7(2):179-186
11. Offit K, Kohut K, Clagett B, Wadsworth EA, Lafaro KJ, Cummings S et al (2006) Cancer genetic testing and assisted reproduction. J Clin Oncol 24(29):4775-4781
12. Dekeuwer C, Bateman S (2013) Much more than a gene: hereditary breast and ovarian cancer, reproductive choices and family life. Med Health Care Philos 16:231-244
13. Kotsopoulos J, Librach CL, Lubinski J, Gronwald J, Kim-Sing C, Ghadirian P et al (2008) Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. Cancer Causes Control 19(10):1111-1119
14. Jasper MJ, Liebelt J, Hussey ND (2008) Preimplantation genetic diagnosis for BRCA1 exon 13 duplication mutation using linked polymorphic markers resulting in a live birth. Prenat Diagn 28(4):292-298
15. Spits C, De Rycke M, Van Ranst N, Verpoest W, Lissens W, Van Steirteghem A et al (2007) Preimplantation genetic diagnosis for cancer predisposition syndromes. Prenat Diagn 27(5):447-456
16. Sagi M, Weinberg N, Eilat A, Aizenman E, Werner M, Girsh E et al (2009) Preimplantation genetic diagnosis for BRCA1/2 - a novel clinical experience. Prenat Diagn 29(5):508-513
17. Tung N (2011) Management of women with BRCA mutations: a 41-year-old woman with a BRCA mutation and a recent history of breast cancer. JAMA 305(21):2211-2220
18. Ramon YCT, Polo A, Martinez O, Gimenez C, Arjona C, Llort G et al (2012) Preimplantation genetic diagnosis for inherited breast cancer: first clinical application and live birth in Spain. Fam Cancer 11(2):175-179
19. Sheldon T (2008) Netherlands debates screening for breast cancer. BMJ 336(7656):1270
20. Integraal Kankercentrum Nederland, Nationaal Borstkanker Overleg Nederland: Breast cancer, Dutch guideline, version 2.0. http://www.oncoline.nl/ breastcancer. Accessed 27 Feb 2014
21. Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M et al (2011) Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without Magnetic Resonance Imaging. J Clin Oncol 29(13):1664-1669
22. Magli MC, Van den Abbeel E, Lundin K, Royere D, Van der Elst J, Gianaroli L, Committee of the Special Interest Group on Embryology (2008) Revised guidelines for good practice in IVF laboratories. Hum Reprod 23(6):1253-1262
23. Harton G, Braude P, Lashwood A, Schmutzler A, Traeger-Synodinos J, Wilton L et al (2011) ESHRE PGD consortium best practice guidelines for organization of a PGD centre for PGD/preimplantation genetic screening. Hum Reprod 26(1):14-24
24. Drüsedau M, Dreesen JC, Derks-Smeets I, Coonen E, Van Golde R, van Echten-Arends J et al (2013) PGD for hereditary breast and ovarian cancer: the route to universal tests for BRCA1 and BRCA2 mutation carriers. Eur J Hum Genet 21(12):1361-1368
25. Zegers-Hochschild F, Adamson GD, de Mouzon J, Ishihara O, Mansour R, Nygren K et al (2009) International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology, 2009. Fertil Steril 92(5):1520-1524
26. Desmyttere S, De Rycke M, Staessen C, Liebaers I, De Schrijver F, Verpoest W et al (2012) Neonatal follow-up of 995 consecutively born children after embryo biopsy for PGD. Hum Reprod 27(1):288-293
27. Oktay K, Kim JY, Barad D, Babayev SN (2010) Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol 28(2):240-244
28. Dreesen J, Drusedau M, Smeets H, de Die-Smulders C, Coonen E, Dumoulin J et al (2008) Validation of preimplantation genetic diagnosis by PCR analysis: genotype comparison of the blastomere and corresponding embryo, implications for clinical practice. Mol Human Reprod 14(10):573-579
29. Wilton L, Thornhill A, Traeger-Synodinos J, Sermon KD, Harper JC (2009) The causes of misdiagnosis and adverse outcomes in PGD. Hum Reprod 24(5):1221-1228
30. Borry P, Evers-Kiebooms G, Cornel MC, Clarke A, Dierickx K (2009) Genetic testing in asymptomatic minors: background considerations towards ESHG Recommendations. Eur J Hum Genet 17(6):711-719
31. Rodriguez-Wallberg KA, Oktay K (2012) Fertility preservation and pregnancy in women with and without BRCA mutation-positive breast cancer. Oncologist 17(11):1409-1417
32. Peate M, Meiser B, Friedlander M, Zorbas H, Rovelli S, Sansom-Daly U et al (2011) It's now or never: fertility-related knowledge, decision-making preferences, and treatment intentions in young women with breast cancer - an Australian fertility decision aid collaborative group study. J Clin Oncol 29(13):1670-1677
33. Rijnsburger AJ, Obdeijn IM, Kaas R, Tilanus-Linthorst MM, Boetes C, Loo CE et al (2010) BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol 28(36):5265-5273
34. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM et al (2008) Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26(26):4282-4288
35. Zreik TG, Mazloom A, Chen Y, Vannucci M, Pinnix CC, Fulton S et al (2010) Fertility drugs and the risk of breast cancer: a meta-analysis and review. Breast Cancer Res Treat 124(1):13-26
36. Narod SA (2006) Modifiers of risk of hereditary breast cancer. Oncogene 25(43):5832-5836
37. Gauthier E, Paoletti X, Clavel-Chapelon F (2004) Breast cancer risk associated with being treated for infertility: results from the French E3N cohort study. Hum Reprod 19(10):2216-2221
38. Braga C, Negri E, La Vecchia C, Parazzini F, Dal Maso L, Franceschi S (1996) Fertility treatment and risk of breast cancer. Hum Reprod 11(2):300-303
39. Grabrick DM, Vierkant RA, Anderson KE, Cerhan JR, Anderson VE, Seller TA (2002) Association of correlates of endogenous hormonal exposure with breast cancer risk in 426 families (United States). Cancer Causes Control 13(4):333-341